P/B
22,1
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
$30B
Market Cap • 10/23/2026
2003
(23 years)
Founded
2004
(22 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,2
P/EBITDA
28,4
P/OCF
33,8
P/FCF
37,8
P/E
41,6
BVPS
10,1
EPS
5,9
Market Cap
Market Cap
30B
EV
27,9B
EV/Revenue
5,8
EV/EBITDA
26,5
EV/EBIT
27,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,6%
Total Yield
-0,6%
Payout
0%
Retained Earnings
-6,3B
Profitability
Gross Margin
79,7%
EBITDA Margin
22%
EBIT Margin
20,8%
Net Margin
16,8%
D&A/EBITDA
0%
R&D/Revenue
31,4%
Capex/Revenue
1,9%
Capex/D&A
167,9%
Capex/OCF
10,4%
SBC/OCF
38%
% PPE
13,3%
% Goodwill
0%
ROE
100,7%
ROIC
102,4%
Growth
CAGR Revenue 5Y
47,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,1
Quick Ratio
2,8
Interest Coverage
307,6%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!